Did the 31 biotechs who pulled IPOs since 2003 destroy value? By and large, no-thanks to a growing variety of financing and exit options, most thanks to Pharma's increasing appetite for high-value deals and deeper private equity pockets.
Roger Longman
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.
